Maridebart cafraglutide
Also known as MariTide, AMG 133
Maridebart cafraglutide (MariTide) is an experimental long-acting injection combining GLP-1 activation with GIP blocking, dosed as infrequently as monthly and showing strong weight loss in trials.
How one dose clears
modeled over ~6 half-lives- Half-life
- 3.0 weeks
- Time to peak (Tmax)
- 7.0 days
- Steady state
- ~90 days
- Typical dose
- 140 mg
Investigational peptide–antibody conjugate (GLP-1 receptor agonist + GIP receptor antagonist) for obesity, designed for monthly or less-frequent dosing.
Mechanism of action
Two GLP-1 analog peptides conjugated to an anti-GIPR antibody give a very long half-life; combines GLP-1 agonism with GIP-receptor antagonism.
Investigational — not approved. Half-life ~21 days supports monthly dosing; trial doses vary widely, so the default here is illustrative.
References
Track Maridebart cafraglutide for free
Log your doses and PeptideBuddy models Maridebart cafraglutide's half-life into a live chart so you always know how much is active — plus reminders, reconstitution and protocol planning.
Start tracking freeFree. No card required.